Market Research Logo

Head And Neck Cancer Squamous Cell Carcinoma - Pipeline Review, H2 2015

Head And Neck Cancer Squamous Cell Carcinoma - Pipeline Review, H2 2015

Summary

Global Markets Direct’s, ‘Head And Neck Cancer Squamous Cell Carcinoma - Pipeline Review, H2 2015’, provides an overview of the Head And Neck Cancer Squamous Cell Carcinoma’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Head And Neck Cancer Squamous Cell Carcinoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Head And Neck Cancer Squamous Cell Carcinoma and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Head And Neck Cancer Squamous Cell Carcinoma
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Head And Neck Cancer Squamous Cell Carcinoma and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Head And Neck Cancer Squamous Cell Carcinoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Head And Neck Cancer Squamous Cell Carcinoma pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
Reasons to buy
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Head And Neck Cancer Squamous Cell Carcinoma
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Head And Neck Cancer Squamous Cell Carcinoma pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


Introduction
Global Markets Direct Report Coverage
Head And Neck Cancer Squamous Cell Carcinoma Overview
Therapeutics Development
Pipeline Products for Head And Neck Cancer Squamous Cell Carcinoma - Overview
Pipeline Products for Head And Neck Cancer Squamous Cell Carcinoma - Comparative Analysis
Head And Neck Cancer Squamous Cell Carcinoma - Therapeutics under Development by Companies
Head And Neck Cancer Squamous Cell Carcinoma - Therapeutics under Investigation by Universities/Institutes
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Unknown Stage Products
Head And Neck Cancer Squamous Cell Carcinoma - Products under Development by Companies
Head And Neck Cancer Squamous Cell Carcinoma - Products under Investigation by Universities/Institutes
Head And Neck Cancer Squamous Cell Carcinoma - Companies Involved in Therapeutics Development
AB Science SA
AbbVie Inc.
Acceleron Pharma, Inc.
Altor BioScience Corporation
Amgen Inc.
Ascenta Therapeutics, Inc.
Astex Pharmaceuticals, Inc.
AstraZeneca Plc
AVEO Pharmaceuticals, Inc.
BIND Therapeutics, Inc.
Bionovis SA
Boehringer Ingelheim GmbH
Bristol-Myers Squibb Company
CEL-SCI Corporation
Cellceutix Corporation
Celldex Therapeutics, Inc.
Celltrion, Inc.
Centrose LLC
Critical Outcome Technologies Inc.
Daiichi Sankyo Company, Limited
Eisai Co., Ltd.
Eli Lilly and Company
Etubics Corporation
F. Hoffmann-La Roche Ltd.
G&E Herbal Biotechnology Co., Ltd.
Genentech, Inc.
Genexine, Inc.
Genzyme Corporation
GlaxoSmithKline Plc
Gliknik, Inc.
Glycotope GmbH
Hanmi Pharmaceuticals, Co. Ltd.
ImmunoGen, Inc.
Immunomedics, Inc.
Immunovative Therapies, Ltd.
Incyte Corporation
Innate Pharma SA
Inovio Pharmaceuticals, Inc.
Karyopharm Therapeutics, Inc.
Laboratoires Pierre Fabre SA
Loxo Oncology, Inc.
Mabion SA
MacroGenics, Inc.
MedImmune, LLC
Merck & Co., Inc.
Merck KGaA
Mirati Therapeutics Inc.
Molplex Ltd.
Novartis AG
Oncobiologics, Inc.
Oncolytics Biotech Inc.
Onconova Therapeutics, Inc.
OncoSec Medical Inc.
Ono Pharmaceutical Co., Ltd.
OXiGENE, Inc.
Panacea Biotec Limited
PCI Biotech AS
Pfizer Inc.
Shanghai Henlius Biotech Co., Ltd.
Shenzen SiBiono GeneTech Co., Ltd
Shionogi & Co., Ltd.
Sillajen Biotherapeutics
Sorrento Therapeutics, Inc.
Symphogen A/S
Synta Pharmaceuticals Corp.
Takara Bio Inc.
Threshold Pharmaceuticals, Inc.
VasGene Therapeutics, Inc.
VentiRx Pharmaceuticals, Inc.
Virttu Biologics Limited
Viventia Bio Inc.
Head And Neck Cancer Squamous Cell Carcinoma - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
ABBV-221 - Drug Profile
AdIL-24 - Drug Profile
afatinib dimaleate - Drug Profile
AlloVax - Drug Profile
alpelisib - Drug Profile
ALT-803 - Drug Profile
AMG-319 - Drug Profile
Antibodies to Inhibit FRMD4A for Oncology - Drug Profile
Antisense Oligonucleotide to Target EGFR for Head and Neck Cancer Squamous Cell Carcinoma - Drug Profile
AT-406 - Drug Profile
AV-203 - Drug Profile
avelumab - Drug Profile
AZD-6738 - Drug Profile
AZD-9150 - Drug Profile
bleomycin sulfate - Drug Profile
BMS-986016 - Drug Profile
BNV-003 - Drug Profile
buparlisib hydrochloride - Drug Profile
capmatinib - Drug Profile
Cellular Immunotherapy for Oncology - Drug Profile
Cellular Immunotherapy to Target EGFR for Head and Neck Cancer Squamous Cell Carcinoma - Drug Profile
cetuximab - Drug Profile
cetuximab biobetter - Drug Profile
cetuximab biosimilar - Drug Profile
cetuximab biosimilar - Drug Profile
cetuximab biosimilar - Drug Profile
cetuximab biosimilar - Drug Profile
cetuximab biosimilar - Drug Profile
cetuximab biosimilar - Drug Profile
COTI-2 - Drug Profile
dalantercept - Drug Profile
DNA IL-12 - Drug Profile
docetaxel - Drug Profile
DPV-001 - Drug Profile
DTP-348 - Drug Profile
duligotuzumab - Drug Profile
durvalumab - Drug Profile
durvalumab + tremelimumab - Drug Profile
E-7046 - Drug Profile
EDC-2 - Drug Profile
elgemtumab - Drug Profile
enoblituzumab - Drug Profile
epacadostat - Drug Profile
everolimus - Drug Profile
ficlatuzumab - Drug Profile
futuximab - Drug Profile
ganetespib - Drug Profile
gedatolisib - Drug Profile
Gene Therapy to Activate p53 for Head and Neck Squamous Cell Carcinoma - Drug Profile
Gene Therapy to Activate p53 for Oncology - Drug Profile
GL-0817 - Drug Profile
golvatinib tartrate - Drug Profile
GS-10 - Drug Profile
GSK-2636771 - Drug Profile
GSK-2849330 - Drug Profile
GSK-3174998 - Drug Profile
GX-051 - Drug Profile
HF-10 - Drug Profile
HSV-1716 - Drug Profile
IC-1001 - Drug Profile
IMGN-289 - Drug Profile
INO-3106 - Drug Profile
INO-3112 - Drug Profile
IPH-2201 - Drug Profile
JX-929 - Drug Profile
KGP-94 - Drug Profile
KM-3174 - Drug Profile
lenvatinib - Drug Profile
Leukocyte Interleukin - Drug Profile
LGK-974 - Drug Profile
lirilumab - Drug Profile
LOXO-101 - Drug Profile
lumretuzumab - Drug Profile
masitinib - Drug Profile
merestinib - Drug Profile
MGCD-265 - Drug Profile
Monoclonal Antibodies to Antagonize Frizzled Receptors for Breast Cancer and Head And Neck Cancer Squamous Cell Carcinoma - Drug Profile
Monoclonal Antibody to Target CD147 for Pancreatic Adenocarcinoma and Head and Neck Cancer Squamous Cell Carcinoma - Drug Profile
motolimod - Drug Profile
MV-NIS - Drug Profile
nilotinib - Drug Profile
nimotuzumab - Drug Profile
nivolumab - Drug Profile
NP-001 - Drug Profile
olaparib - Drug Profile
onalespib - Drug Profile
Oncolytic Virus to Activate IFN-b for Hepatocellular Carcinoma and Head And Neck Cancer Squamous Cell Carcinoma - Drug Profile
palbociclib - Drug Profile
panitumumab - Drug Profile
patritumab - Drug Profile
pelareorep - Drug Profile
pembrolizumab - Drug Profile
PF-04518600 - Drug Profile
poziotinib - Drug Profile
prexasertib - Drug Profile
Recombinant Peptide to Target EGFR for Oncology - Drug Profile
Recombinant Protein for Oncology - Drug Profile
rigosertib sodium - Drug Profile
S-488210 - Drug Profile
sacituzumab - Drug Profile
SB-01 - Drug Profile
selinexor - Drug Profile
Small Molecules for Head and Neck Cancer Squamous Cell Carcinoma - Drug Profile
Small Molecules to Inhibit 16S rRNA for Head And Neck Cancer Squamous Cell Carcinoma and Oral Cancer - Drug Profile
Small Molecules to Inhibit CREB Protein for Head And Neck Cancer Squamous Cell Carcinoma - Drug Profile
Small Molecules to Inhibit IL-6 for Head and Neck Squamous Cell Carcinoma - Drug Profile
Solarise - Drug Profile
tarloxotinib bromide - Drug Profile
trametinib dimethyl sulfoxide + uprosertib - Drug Profile
urelumab - Drug Profile
Vaccine for HPV Associated Head and Neck Squamous Cell Carcinoma - Drug Profile
vandetanib - Drug Profile
varlilumab - Drug Profile
Vas-01 - Drug Profile
VB-4847 - Drug Profile
vinflunine ditartrate - Drug Profile
Head And Neck Cancer Squamous Cell Carcinoma - Recent Pipeline Updates
Head And Neck Cancer Squamous Cell Carcinoma - Dormant Projects
Head And Neck Cancer Squamous Cell Carcinoma - Discontinued Products
Head And Neck Cancer Squamous Cell Carcinoma - Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Head And Neck Cancer Squamous Cell Carcinoma, H2 2015
Number of Products under Development for Head And Neck Cancer Squamous Cell Carcinoma - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Number of Products under Development by Companies, H2 2015 (Contd..1)
Number of Products under Development by Companies, H2 2015 (Contd..2)
Number of Products under Development by Companies, H2 2015 (Contd..3)
Number of Products under Development by Companies, H2 2015 (Contd..4)
Number of Products under Development by Companies, H2 2015 (Contd..5)
Number of Products under Investigation by Universities/Institutes, H2 2015
Comparative Analysis by Late Stage Development, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Development, H2 2015
Comparative Analysis by Unknown Stage Development, H2 2015
Products under Development by Companies, H2 2015
Products under Development by Companies, H2 2015 (Contd..1)
Products under Development by Companies, H2 2015 (Contd..2)
Products under Development by Companies, H2 2015 (Contd..3)
Products under Development by Companies, H2 2015 (Contd..4)
Products under Development by Companies, H2 2015 (Contd..5)
Products under Development by Companies, H2 2015 (Contd..6)
Products under Development by Companies, H2 2015 (Contd..7)
Products under Investigation by Universities/Institutes, H2 2015
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by AB Science SA, H2 2015
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by AbbVie Inc., H2 2015
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Acceleron Pharma, Inc., H2 2015
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Altor BioScience Corporation, H2 2015
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Amgen Inc., H2 2015
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Ascenta Therapeutics, Inc., H2 2015
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Astex Pharmaceuticals, Inc., H2 2015
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by AstraZeneca Plc, H2 2015
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by AVEO Pharmaceuticals, Inc., H2 2015
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by BIND Therapeutics, Inc., H2 2015
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Bionovis SA, H2 2015
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Boehringer Ingelheim GmbH, H2 2015
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Bristol-Myers Squibb Company, H2 2015
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by CEL-SCI Corporation, H2 2015
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Cellceutix Corporation, H2 2015
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Celldex Therapeutics, Inc., H2 2015
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Celltrion, Inc., H2 2015
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Centrose LLC, H2 2015
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Critical Outcome Technologies Inc., H2 2015
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Daiichi Sankyo Company, Limited, H2 2015
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Eisai Co., Ltd., H2 2015
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Eli Lilly and Company, H2 2015
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Etubics Corporation, H2 2015
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by F. Hoffmann-La Roche Ltd., H2 2015
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by G&E Herbal Biotechnology Co., Ltd., H2 2015
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Genentech, Inc., H2 2015
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Genexine, Inc., H2 2015
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Genzyme Corporation, H2 2015
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by GlaxoSmithKline Plc, H2 2015
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Gliknik, Inc., H2 2015
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Glycotope GmbH, H2 2015
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Hanmi Pharmaceuticals, Co. Ltd., H2 2015
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by ImmunoGen, Inc., H2 2015
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Immunomedics, Inc., H2 2015
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Immunovative Therapies, Ltd., H2 2015
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Incyte Corporation, H2 2015
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Innate Pharma SA, H2 2015
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Inovio Pharmaceuticals, Inc., H2 2015
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Karyopharm Therapeutics, Inc., H2 2015
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Laboratoires Pierre Fabre SA, H2 2015
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Loxo Oncology, Inc., H2 2015
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Mabion SA, H2 2015
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by MacroGenics, Inc., H2 2015
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by MedImmune, LLC, H2 2015
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Merck & Co., Inc., H2 2015
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Merck KGaA, H2 2015
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Mirati Therapeutics Inc., H2 2015
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Molplex Ltd., H2 2015
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Novartis AG, H2 2015
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Oncobiologics, Inc., H2 2015
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Oncolytics Biotech Inc., H2 2015
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Onconova Therapeutics, Inc., H2 2015
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by OncoSec Medical Inc., H2 2015
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Ono Pharmaceutical Co., Ltd., H2 2015
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by OXiGENE, Inc., H2 2015
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Panacea Biotec Limited, H2 2015
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by PCI Biotech AS, H2 2015
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Pfizer Inc., H2 2015
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Shanghai Henlius Biotech Co., Ltd., H2 2015
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Shenzen SiBiono GeneTech Co., Ltd, H2 2015
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Shionogi & Co., Ltd., H2 2015
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Sillajen Biotherapeutics, H2 2015
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Sorrento Therapeutics, Inc., H2 2015
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Symphogen A/S, H2 2015
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Synta Pharmaceuticals Corp., H2 2015
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Takara Bio Inc., H2 2015
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Threshold Pharmaceuticals, Inc., H2 2015
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by VasGene Therapeutics, Inc., H2 2015
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by VentiRx Pharmaceuticals, Inc., H2 2015
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Virttu Biologics Limited, H2 2015
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Viventia Bio Inc., H2 2015
Assessment by Monotherapy Products, H2 2015
Assessment by Combination Products, H2 2015
Number of Products by Stage and Target, H2 2015
Number of Products by Stage and Mechanism of Action, H2 2015
Number of Products by Stage and Route of Administration, H2 2015
Number of Products by Stage and Molecule Type, H2 2015
Head And Neck Cancer Squamous Cell Carcinoma Therapeutics - Recent Pipeline Updates, H2 2015
Head And Neck Cancer Squamous Cell Carcinoma - Dormant Projects, H2 2015
Head And Neck Cancer Squamous Cell Carcinoma - Dormant Projects (Contd..1), H2 2015
Head And Neck Cancer Squamous Cell Carcinoma - Dormant Projects (Contd..2), H2 2015
Head And Neck Cancer Squamous Cell Carcinoma - Dormant Projects (Contd..3), H2 2015
Head And Neck Cancer Squamous Cell Carcinoma - Discontinued Products, H2 2015
Head And Neck Cancer Squamous Cell Carcinoma - Discontinued Products (Contd..1), H2 2015
List of Figures
Number of Products under Development for Head And Neck Cancer Squamous Cell Carcinoma, H2 2015
Number of Products under Development for Head And Neck Cancer Squamous Cell Carcinoma - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Number of Products under Investigation by Universities/Institutes, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Products, H2 2015
Assessment by Monotherapy Products, H2 2015
Assessment by Combination Products, H2 2015
Number of Products by Top 10 Targets, H2 2015
Number of Products by Stage and Top 10 Targets, H2 2015
Number of Products by Top 10 Mechanism of Actions, H2 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
Number of Products by Top 10 Routes of Administration, H2 2015
Number of Products by Stage and Top 10 Routes of Administration, H2 2015
Number of Products by Top 10 Molecule Types, H2 2015
Number of Products by Stage and Top 10 Molecule Types, H2 2015

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report